Glycaemic efficacy and safety of linagliptin for the management of non-cardiac surgery patients with type 2 diabetes in a real-world setting: Lina-Surg study

References

• Inzucchi SE. Clinical practice. Management of hyperglycemia in the hospital setting. N Engl J Med. 2006;355:1903–1911.
   PubMed Web of Science ®Google Scholar
• Lara-Rojas CM, Pérez-Belmonte LM, López-Carmona MD, et al. National trends in diabetes mellitus hospitalization in Spain 1997–2010: analysis of over 5.4 millions of admissions. Eur J Intern Med. 2019;60:83–89.
   PubMed Web of Science ®Google Scholar
• Umpierrez GE, Hellman R, Korytkowski MT, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:16–38.
   PubMed Web of Science ®Google Scholar
• Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449–461.
   PubMed Web of Science ®Google Scholar
• Umpierrez GE, Smiley D, Zisman A, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). Diab Care. 2007;30:2181–2186.
   PubMed Web of Science ®Google Scholar
• Umpierrez GE, Smiley D, Jacobs S, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). Diab Care. 2011;34:256–261.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Diabetes care in the hospital: standards of medical care in diabetes – 2019. Diab Care. 2019;42:S173–S81.
   PubMed Web of Science ®Google Scholar
• Boucai L, Southern WN, Zonszein J. Hypoglycemia-associated mortality is not drug-associated but linked to comorbidities. Am J Med. 2011;124:1028–1035.
   PubMed Web of Science ®Google Scholar
• Umpierrez GE, Palacio A, Smiley D. Sliding scale insulin use: myth or insanity? Am J Med. 2007;120:563.
   PubMed Web of Science ®Google Scholar
• Donner TW, Flammer KM. Diabetes management in the hospital. Med Clin North Am. 2008;92:407–425.
   PubMed Web of Science ®Google Scholar
• Mendez CE, Umpierrez GE. Pharmacotherapy for hyperglycemia in noncritically ill hospitalized patients. Diab Spectr. 2014;27:180–188.
   PubMedGoogle Scholar
• Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diab Care. 2006;29:2632–2637.
   PubMed Web of Science ®Google Scholar
• Umpierrez GE, Gianchandani R, Smiley D, et al. Safety and efficacy of sitagliptin therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes: a pilot, randomized, controlled study. Diab Care. 2013;36:3430–3435.
   PubMed Web of Science ®Google Scholar
• Pasquel FJ, Gianchandani R, Rubin DJ, et al. Efficacy of sitagliptin for the hospital management of general medicine and surgery patients with type 2 diabetes (Sita-Hospital): a multicentre, prospective, open-label, non-inferiority randomized trial. Lancet Diab Endocrinol. 2017;5:125–133.
   PubMed Web of Science ®Google Scholar
• Garg R, Schuman B, Hurwitz S, et al. Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients. BMJ Open Diab Res Care. 2017;5:e000394.
   PubMed Web of Science ®Google Scholar
• Pérez-Belmonte LM, Gómez-Doblas JJ, Millán-Gómez M, et al. Use of linagliptin for the management of medicine department inpatients with type 2 diabetes in real-world clinical practice (Lina-Real-World Study). J Clin Med. 2018;7:271–286.
   PubMed Web of Science ®Google Scholar
• Vellanki P, Rasouli N, Baldwin D, et al. Glycaemic efficacy and safety of linagliptin compared to basal-bolus insulin regimen in patients with type 2 diabetes undergoing non-cardiac surgery: a multicenter randomized clinical trial. Diab Obes Metab. 2019;21:837–843.
   Web of Science ®Google Scholar
• Zinman B, Ahrén B, Neubacher D, et al. Efficacy and cardiovascular safety of linagliptin as an add-on to insulin in type 2 diabetes: a pooled comprehensive post hoc analysis. Can J Diab. 2016;40:50–57.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321:69–79.
   PubMed Web of Science ®Google Scholar
• Pasquel FJ, Gomez-Huelgas R, Anzola I, et al. Predictive value of admission hemoglobin A1c on inpatient glycemic control and response to insulin therapy in medicine and surgery patients with type 2 diabetes. Diab Care. 2015;38:202–203.
   Web of Science ®Google Scholar
• Umpierrez GE, Hor T, Smiley D, et al. Comparison of impatient insulin regiments with determir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;97:564–569.
   Google Scholar
• Nauck MA, Meier JJ. Sitagliptin plus basal insulin: simplifying in-hospital diabetes treatment? Lancet Diab Endocrinol. 2017;5:83–85.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes – 2019. Diab Care. 2019;42:S90–S102.
   PubMed Web of Science ®Google Scholar
• Umpierrez GE, Korytkowski M. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes? Insulin therapy has proven itself and is considered the mainstay of treatment. Diab Care. 2013;36:2112.
   PubMed Web of Science ®Google Scholar
• Fayfman M, Galindo RJ, Rubin DJ, et al. A randomized controlled trial on the safety and efficacy of exenatide therapy for the inpatient management of general medicine and surgery patients with type 2 diabetes. Diab Care. 2019;42:450–456.
   PubMed Web of Science ®Google Scholar
• Umpierrez G, Korytkowski M. Diabetic emergencies-ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol. 2016;12:222–232.
   PubMed Web of Science ®Google Scholar
• Deacon CF, Holst JJ. Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes. Expert Opin Investig Drugs. 2010;19:133–140.
   PubMed Web of Science ®Google Scholar